Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17869320 | 0.83 | CYP11B2 (0.45) | CYP11B2KDM4EITGAVITGB6AADAT | |
| SCHEMBL29788958 | 0.83 | CYP11B2 (0.45) | CYP11B2KDM4EITGAVITGB6AADAT | |
| SCHEMBL22446022 | 0.76 | KMT2A (0.46) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL21832037 | 0.76 | CYP11B2 (0.44) | CYP11B2AADATPLK1CSNK2A1PLK3 | |
| SCHEMBL22445870 | 0.74 | CYP11B2 (0.38) | CYP11B2KDM4EAADATPLK1CSNK2A1 | |
| SCHEMBL7334999 | 0.74 | MMP3 (0.39) | BRD4KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11572505 | 0.73 | PDK2 (0.43) | SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL22151080 | 0.72 | CYP11B2 (0.44) | CYP11B2KDM4EAADATPLK1CSNK2A1 | |
| SCHEMBL22908471 | 0.72 | CYP11B2 (0.44) | CYP11B2AADATPLK1CSNK2A1PLK3 | |
| SCHEMBL17868933 | 0.72 | JAK2 (0.36) | BRD4KDM4EITGAVITGB6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-107406451-B | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3240791-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP11B2 4560/4885BRD4 487/4885KDM4E 994/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CYP11B2 4560/4885BRD4 487/4885KDM4E 994/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CYP11B2 4560/4885BRD4 487/4885KDM4E 994/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP11B2 4560/4885BRD4 487/4885KDM4E 994/4885 |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CYP11B2 4545/4885BRD4 503/4885KDM4E 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.